Colorectal cancer is the third most common cancer in Europe with an estimated 420,000 cases and 150,000 related deaths in 2012. Of total CRC cases, it is thought that approximately 50-55 % involve RAS mutations.
Current treatment for MSS RAS mt mCRC is primarily based on 5-fluoruracil based chemotherapy +/- bevacizumab. However, there are limited treatment options for patients with this type of cancer when they develop resistance to standard treatment. Targetting MSS RAS mt disease is difficult and has not evolved significantly in recent years.